AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12173299
Drug: Diphtheria toxoid
RxNorm normalized name: diphtheria toxoid
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria toxoid vaccine
Trial: 10433584
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine
Trial: 1176233
Drug: Decreasing dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing dose (N = 12)
Trial: 29952075
Drug: In situ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In situ photo‐immunotherapy (ISPI) with 808 nm laser irradiation
Trial: 29952075
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod alone
Trial: 28068786
Drug: Intrapericardial tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapericardial tranexamic acid 50 mg/kg in 20 mL of saline before sternal closure (Group B)
Trial: 28068786
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous tranexamic acid 20 mg/kg after sternotomy and intrapericardial tranexamic acid 50 mg/kg before sternal closure (Group C)
Trial: 23483571
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg carvedilol tablets
Trial: 19453736
Drug: Emollient used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient used as maintenance therapy after topical corticotherapy
Trial: 12434478
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid therapy
Trial: 26589819
Drug: Lisinopril vs
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril vs Chlorthalidone
Trial: 12352270
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg alone (medication management)
Trial: 12853193
Drug: Carvedilol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (target dose 25 mg twice daily)
Trial: 2616824
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg salbutamol via Rotacaps
Trial: 2616824
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg salbutamol via Rotacaps
Trial: 2616824
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg salbutamol via nebulizer
Trial: 2616824
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg salbutamol via nebulizer
Trial: 30879186
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CTG)
Trial: 15679494
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mechanical bowel preparation)
Trial: 14756852
Drug: Sumatriptan formulations
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan formulations (various routes of administration)
Trial: 14756852
Drug: Placebo formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulations (matching sumatriptan formulations)
Trial: 31826802
Drug: Paclitaxel micellar
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel micellar (250 mg/m2, 1-h infusion) + carboplatin (AUC 5-6)
Trial: 31826802
Drug: Cr-EL paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cr-EL paclitaxel (175 mg/m2, 3-h infusion) + carboplatin (AUC 5-6)
Trial: 25455873
Drug: Lidocaine (8.5-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (8.5-mL dose administered to the portio, cervix, and uterus)
Trial: 9085313
Drug: Cefpodoxime 200
RxNorm normalized name: cefpodoxime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime 200 mg
Trial: 9085313
Drug: Cefuroxime 500
RxNorm normalized name: cefuroxime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 500 mg
Trial: 2393281
Drug: Cefprozil 500
RxNorm normalized name: cefprozil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil 500 mg
Trial: 9085313
Drug: Loracarbef 400
RxNorm normalized name: loracarbef 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef 400 mg
Trial: 29885994
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg intravenously every 2 weeks for 4 cycles)
Trial: 29885994
Drug: Corticosteroids (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (methylprednisolone 500 mg/day intravenously for 3 days, then tapered, followed by 10 mg/day oral prednisone for 2 months)
Trial: 16243240
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (preemptive, posttreatment, no-treatment)
Trial: 2185965
Drug: 2% fenticonazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% fenticonazole spray
Trial: 2185965
Drug: 1% cyclopyroxolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% cyclopyroxolamine spray
Trial: 29244743
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of creatine nitrate (CNH)
Trial: 29244743
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of creatine nitrate (CNL)
Trial: 26617438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of XAT and morphine (20 mg and 30 mg, respectively)
Trial: 26617438
Drug: XAT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAT treatment
Trial: 18214123
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg daily for eight weeks
Trial: 18214123
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg daily for eight weeks
Trial: 15259325
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of standard training for spatial scanning and optokinetic stimulation
Trial: 15259325
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for spatial scanning
Trial: 10929897
Drug: IgG serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG serum antibodies
Trial: 26932169
Drug: SLIT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT plus vitamin D supplementation (1000 IU daily)
Trial: 1974143
Drug: Propranolol LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol LA (160 mg)
Trial: 1968912
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK (100 mg)
Trial: 437431
Drug: β-sitosterol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-sitosterol (250 mg/kg/day)
Trial: 437431
Drug: chenic acid
RxNorm normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chenic acid (10 mg/kg/day)
Trial: 17374038
Drug: Naltrexone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone + Cognitive Behavioral Therapy (CBT)
Trial: 17374038
Drug: Naltrexone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone + Motivational Enhancement Therapy (MET)
Trial: 15353385
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/day (12 mg bid)
Trial: 9312920
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg
Trial: 30833149
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) filler injection
Trial: 30833149
Drug: Polylactic Acid
RxNorm normalized name: Polylactic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polylactic Acid (PLA) filler injection
Trial: 28831752
Drug: Atrasentan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.5 mg once daily for 8 weeks
Trial: 28831752
Drug: Atrasentan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 1.25 mg once daily for 8 weeks
Trial: 22973945
Drug: Nurse-led intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led intervention including weekly nutrition and exercise education, exercise sessions, and nurse support (n = 51)
Trial: 21301811
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 10 IU
Trial: 21301811
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 20 IU
Trial: 14731173
Drug: Hollow screw
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hollow screw (HS) implants
Trial: 14731173
Drug: Hollow cylinder
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hollow cylinder (HC) implants
Trial: 9208074
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.3 mg.kg‐1 with intravenous midazolam 2 mg
Trial: 8355505
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose cytosine arabinoside (VLD-AC)
Trial: 8355505
Drug: Low-dose aclarubicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aclarubicin (LC-ACR)
Trial: 3325317
Drug: split‐virion influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: split‐virion influenza vaccine (MFV‐Ject, Institut Merieux)
Trial: 31629915
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four cycles followed by nivolumab 3 mg/kg every 2 weeks
Trial: 25139589
Drug: Oxcarbazepine (1800-2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (1800-2400 mg)
Trial: 20815183
Drug: Modafinil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (2 x 100 mg)
Trial: 8564565
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ATRA + chemotherapy
Trial: 23447846
Drug: Fluid intake
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid intake of 300 ml/h
Trial: 19920002
Drug: Insulin sensitization
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin sensitization
Trial: 19920002
Drug: Insulin provision
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin provision
Trial: 15005471
Drug: School-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based oral health education programme
Trial: 8767563
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg midazolam
Trial: 16965682
Drug: Docetaxel (made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (made in Beijing) 75 mg/m² plus cisplatin 70 mg/m²
Trial: 16965682
Drug: Docetaxel (made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (made in Jiangsu) 75 mg/m² plus cisplatin 70 mg/m²
Trial: 15215483
Drug: Folate therapy
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate therapy
Trial: 12767735
Drug: Standard haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard haemodialysis treatment
Trial: 10867427
Drug: 40% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% chlorhexidine varnish (EC40) after dental treatment
Trial: 10867427
Drug: Full dental
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dental treatment only
Trial: 8637402
Drug: Melanotan-II (MT-II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanotan-II (MT-II) at doses of 0.01 mg/kg, escalated to 0.025 mg/kg and 0.03 mg/kg
Trial: 3927332
Drug: Pizotifene (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifene (4 mg daily for 3 days orally)
Trial: 3927332
Drug: Naloxone-HCI (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone-HCI (0.8 mg intravenously)
Trial: 23300343
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment (control group)
Trial: 2534552
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream
Trial: 28794206
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS) daily from ≤20 wk gestation to 6 mo postpartum
Trial: 28794206
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient (MMN) capsule daily from ≤20 wk gestation to 6 mo postpartum
Trial: 20495502
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin of < 9.0 g/dL)
Trial: 15278580
Drug: 0.05 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg(‐1) vecuronium (low dose group)
Trial: 6375469
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg t.i.d.)
Trial: 17979579
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at a mean dose of 14.22 mg/day, n = 63
Trial: 9537619
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion containing 154 microg phylloquinone
Trial: 350904
Drug: 0.5% astringent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% astringent solution mouthwash
Trial: 28116974
Drug: Original indications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original indications (19 drugs, 31 studies)
Trial: 28116974
Drug: Supplemental indications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental indications (18 drugs, 33 studies)
Trial: 9154884
Drug: Cefuroxime (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (two 1,500 mg doses 12 hours apart after intubation)
Trial: 9154884
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cefuroxime, 17 patients received prophylactic antibiotics)
Trial: 9154884
Drug: Control (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (patients receiving prior antibiotics)
Trial: 9154884
Drug: Control (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (patients not receiving prior antibiotics)
Trial: 28643733
Drug: Gem/Cis (Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gem/Cis (Cisplatin 40 mg/m2 on day 1 and day 8 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Trial: 22983820
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) added to Standard Care (SC)
Trial: 20370452
Drug: Mupirocin applied
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin applied three times weekly (Group II)
Trial: 20370452
Drug: Prior to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to mupirocin treatment
Trial: 15071253
Drug: Atrial therapies
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial therapies OFF
Trial: 26207129
Drug: Clzapine (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clzapine (generic formulation) 100 mg twice daily for 10 days
Trial: 26207129
Drug: Clozaril (brand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozaril (brand name formulation) 100 mg twice daily for 10 days
Trial: 24114865
Drug: High-dose β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose β-blocker (≥50 mg daily equivalent dose of metoprolol succinate)
Trial: 24114865
Drug: Low-dose β-blocker
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose β-blocker with high sST2
Trial: 24114865
Drug: Low-dose β-blocker
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose β-blocker with low sST2
Trial: 24114865
Drug: High-dose β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose β-blocker with high sST2
Trial: 18650733
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (group 1)
Trial: 2405623
Drug: High-dose calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcium heparin
Trial: 2405623
Drug: Low-dose calcium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcium heparin
Trial: 9184614
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 to 20 mg/day)
Trial: 9754892
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro addition of LMWH (1.5 u aXa/ml)
Trial: 26920668
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem
Trial: 26157206
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (30 min/session, 3 sessions/week for 4 weeks)
Trial: 16943451
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil plus 100 mg vitamin E
Trial: 16943451
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil plus 200 mg vitamin E
Trial: 16943451
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil plus 400 mg vitamin E
Trial: 15364138
Drug: Whole brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole brain radiotherapy plus concomitant carboplatin (70 mg/m(2) intravenously for 5 days)
Trial: 10660240
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine (0.125 mg/kg/h)
Trial: 10660240
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine (0.25 mg/kg/h)
Trial: 10660240
Drug: Saline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (6 to 11 mL/h)
Trial: 8157048
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg i.v. dose of flumazenil
Trial: 8157048
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral dose of flumazenil
Trial: 3895918
Drug: Ceftazidime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (50 mg/kg intravenously every eight hours)
Trial: 15254055
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (vincristine 2 mg/m(2), cyclophosphamide 1,200 mg/m(2), doxorubicin 75 mg/m(2) or dactinomycin 1.25 mg/m(2))
Trial: 15254055
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (Regimen A alternating every 3 weeks with ifosfamide 1,800 mg/m(2)/d for 5 days and etoposide 100 mg/m(2)/d for 5 days)
Trial: 11480629
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (no A/V eyeglasses)
Trial: 7946694
Drug: Traditional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional surgical treatment of open carpal tunnel decompression
Trial: 3060211
Drug: Methylphenidate (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (low-dose)
Trial: 31101694
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric bupivacaine (1.15-1.70 mL) injected into the subarachnoid space without prophylactic vasopressors
Trial: 31101694
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (1.8 mL) injected into the subarachnoid space along with prophylactic vasopressors
Trial: 27491027
Drug: Sacral neuromodulation
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral neuromodulation (SNM) therapy with the InterStim® System